Bilateral Oophorectomy and All-Cause Mortality in Women with BRCA1 and BRCA2 Sequence Variations

Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Pål Møller, Tuya Pal, Jeanna M. McCuaig, Christian F. Singer, Beth Y. Karlan, Amber Aeilts, Charis Eng, Andrea Eisen, Louise Bordeleau, William D. Foulkes, Nadine Tung, Fergus J. Couch, Robert Fruscio, Susan L. Neuhausen, Dana Zakalik, Cezary Cybulski, Kelly MetcalfeOlufunmilayo I. Olopade, Ping Sun, Jan Lubinski, Steven A. Narod

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Importance: Preventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined. Objective: To evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation. Design, Setting, and Participants: In this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023. Exposures: Self-reported bilateral oophorectomy (with or without salpingectomy). Main Outcomes and Measures: All-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality. Results: There were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P <.001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P <.001) and 0.43 (95% CI, 0.22-0.90; P =.03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy. Conclusions and Relevance: In this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.

Original languageEnglish
Pages (from-to)484-492
Number of pages9
JournalJAMA Oncology
Volume10
Issue number4
DOIs
StatePublished - Apr 18 2024

Fingerprint

Dive into the research topics of 'Bilateral Oophorectomy and All-Cause Mortality in Women with BRCA1 and BRCA2 Sequence Variations'. Together they form a unique fingerprint.

Cite this